CTRI/2007/091/000024已完成3 期
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion Criteria:
- •- Confirmed acute symptomatic proximal DVT without symptomatic PE OR Confirmed acute symptomatic PE with or without symptomatic DVT
排除标准
- •Legal lower age limitations (country specific)
- •- Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT and/or PE
- •- Other indication for VKA than DVT and/or PE
研究者
相似试验
进行中（未招募）
不适用
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. - ''Einstein''Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.MedDRA version: 6.1Level: PTClassification code 10043566EUCTR2006-004495-13-ITBAYER6,260
进行中（未招募）
不适用
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep- vein thrombosis or pulmonary embolismEUCTR2006-004495-13-LVBayer Healthcare AG7,465
进行中（未招募）
不适用
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep- vein thrombosis or pulmonary embolismEUCTR2006-004495-13-HUBayer Healthcare AG7,400
进行中（未招募）
不适用
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep- vein thrombosis or pulmonary embolismEUCTR2006-004495-13-ATBayer Healthcare AG7,400
进行中（未招募）
不适用
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep- vein thrombosis or pulmonary embolismEUCTR2006-004495-13-NLBayer Healthcare AG7,400